The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients
18 Years
N/A
Female
Breast Cancer
Trial Information
The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients
OBJECTIVES:
Primary
- To determine the association between women's and physicians' participatory
communication behaviors (e.g., patients asking questions, physicians soliciting
questions) on treatment decision-making process and health outcomes.
Secondary
- To capture the language used in the treatment-decision interactions.
- To assess the degree of variation in the language used among physicians and patients
who are active participants and those who are less inclined to participate in the
treatment decision-making interaction.
OUTLINE: Patients and their companions undergo consultation with the physician for treatment
decision making. The treatment discussion is audio/videotaped for approximately 45 minutes.
Patients complete one short survey prior to physician consultation. After the treatment
discussion, patients complete two short surveys, one immediately after the visit in the
waiting room before leaving for the day, and the second one a week after the visit by a
web-based survey or by mail.
PROJECTED ACCRUAL: A total of 300 women with breast cancer and 600 companions of these women
will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Meets one of the following criteria:
- Woman with newly diagnosed early-stage breast cancer
- Caregiver or companion willing to participate in study
PATIENT CHARACTERISTICS:
- Speaks native English or has learned to speak English fluently
- Patient's companion ≥ 18 years old (if applicable)
- Able to complete questionnaires without assistance
- Not pregnant
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
The association between patients' and physicians' participatory communication and psychosocial outcomes.
Outcome Time Frame:
Pre- and post-Initial treatment decision making visit
Safety Issue:
No
Principal Investigator
Thomas J. Kearney, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Cancer Institute of New Jersey
Authority:
United States: Food and Drug Administration
Study ID:
CDR0000635781
NCT ID:
NCT00891969
Start Date:
February 2009
Completion Date:
December 2009
Related Keywords:
- Breast Cancer
- stage I breast cancer
- stage II breast cancer
- stage IIIA breast cancer
- Breast Neoplasms
Name | Location |
|---|---|
| Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | New Brunswick, New Jersey 08903 |
